Literature DB >> 11437944

Primary cutaneous Langerhans cell histiocytosis showing malignant phenotype in an elderly woman: report of a fatal case.

H Itoh1, H Miyaguni, H Kataoka, Y Akiyama, S Tateyama, K Marutsuka, Y Asada, K Ogata, M Koono.   

Abstract

BACKGROUND: Langerhans cell histiocytosis (LCH) is a proliferating disorder of Langerhans cells (LC) that are characterized by the presence of Birbeck granules. LCH has been considered to be a disease of childhood and there have been limited cases of adult LCH. We report here a fatal case of histiocytic tumor showing Langerhans cell phenotype, arising in the skin of a 74-year-old woman.
METHOD: In addition to routine histological and immunohistological sections, electron microscopic examination and human androgen receptor gene (HUMARA) assays were performed.
RESULTS: Histological examination revealed a dense dermal infiltrative proliferation of fairly large tumor cells with abundant ill-defined cytoplasms and oval or indented nuclei, in which numerous eosinophils were associated with the tumor nests. Tumor cells were positive with anti-S-100 and CD1a antibodies but negative with HMB-45 antibody or other epithelial or lymphocytic markers. Ultrastructural analysis showed typical Birbeck granules in the cytoplasm of the tumor cells. HUMARA assay of the tumor tissue revealed the nonrandom X inactivation pattern, indicating the clonal proliferation.
CONCLUSIONS: We diagnosed this tumor as Langerhans cell histiocytosis with a clonal neoplastic phenotype originated in the skin. Although she demonstrated no recurrence nor metastases for 6 months after surgical resection of primary skin lesion and subsequent radiation therapy, the tumor recurred and extended multisystemically, and she died of multiple organ failure 14 months after initial diagnosis. Therefore, we would like to emphasize this case as LC "sarcoma" or "malignant" LCH.

Entities:  

Mesh:

Year:  2001        PMID: 11437944     DOI: 10.1034/j.1600-0560.2001.280707.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature.

Authors:  Boris Dominik Jülg; Sven Weidner; Doris Mayr
Journal:  Virchows Arch       Date:  2005-11-22       Impact factor: 4.064

Review 2.  Cutaneous Langerhans cell sarcoma: a case report and review of the literature.

Authors:  Olga L Bohn; Guillermo Ruiz-Argüelles; Leticia Navarro; Jesus Saldivar; Sergio Sanchez-Sosa
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

3.  Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report.

Authors:  Jong-Sil Lee; Gyung Hyuck Ko; Ho Cheol Kim; In Seok Jang; Kyung-Nyeo Jeon; Jeong-Hee Lee
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

4.  ESHAP therapy effective in a patient with Langerhans cell sarcoma.

Authors:  Akihide Yoshimi; Keiki Kumano; Toru Motokura; Yutaka Takazawa; Satoshi Oota; Shigeru Chiba; Tsuyoshi Takahashi; Masashi Fukayama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2008-04-17       Impact factor: 2.490

5.  Langerhans Cell Sarcoma of the Axillary Lymph Node: A Case Report and Review of the Literature.

Authors:  Aylin Orgen Çallı; Yelda Morgül; İnci Alacacıoğlu; Sadi Bener; Bahriye Payzin
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

6.  Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review.

Authors:  Yaonan Zhang; Zongyang Qu; Fang Fang
Journal:  Oncol Lett       Date:  2016-09-27       Impact factor: 2.967

7.  Unusual cutaneous Langerhans cell sarcoma without extracutaneous involvement.

Authors:  Yang Li; Bin Li; Xiao-ying Tian; Zhi Li
Journal:  Diagn Pathol       Date:  2013-02-06       Impact factor: 2.644

8.  Epstein-Barr Virus-Positive Langerhans Cell Sarcoma: Is There a Link? A Case Report.

Authors:  Yu Guo; Shui-Hong Zhou; Zai-Zai Cao; Yang-Yang Bao; Li-Fang Shen; Hong-Tian Yao
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.